FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
Purpose: To determine the feasibility and safety of combining digoxin as a modulator of the
hypoxia pathway in combination with FOLinic acid, 5-Fluorouracil, IRINotecan and OXaliplatin
(FOLFIRINOX) in patients with resectable pancreatic cancer.